BioMark Diagnostics Expands Research Development in Quebec

Vancouver, British Columbia--(Newsfile Corp. - August 13, 2020) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark"), a developer of proprietary, non-invasive, and accurate diagnostic solutions announced today that the Company is moving parts of its lung cancer research and development operations to LE CAMP, an incubator-accelerator dedicated to tech businesses growth and mentorship.

"This move highlights BioMark's focus on diagnostic development and technological innovation within the healthcare sector," said Rashid Bux, Chief Executive Officer of BioMark Diagnostics Inc. "The renowned LE CAMP site offers a diversity of services adapted to similarly sized development stage companies and offers a significant opportunity to form strategic relationships with other industry leaders. Going forward we intend to invest in human capital and expand our infrastructure in Quebec in order to accelerate the commercialization of our early lung cancer detection platform with IUCPQ (l'Institut universitaire de cardiologie et de pneumologie de Québec) and other excellent strategic partners located across the province. Our institutions have been engaged in clinical studies that have led to very exciting results for potential lung cancer screening."

BioMark's research and development is based on the science of metabolomics and leverages Artificial intelligence (AI) systems that make advances in omics and molecular technologies, such as liquid biopsy, faster and more accurate. The Company focuses on the pivotal role that metabolomics plays in early cancer detection with an aim to improve patient treatment outcome. Metabolomics gives you a precise chemical read out on a person's state of health since it involves the rapid, high throughput characterization of the small molecule metabolites found in an organism. Additionally, BioMark is targeting a Covid-19 screening, which is focused on fundamentally changing how testing will be done on a global basis.

About Le Camp

A cornerstone of Québec City's business community, LE CAMP is a vibrant home where ideas flourish and successful businesses are born. LE CAMP is an incubator-accelerator dedicated to growing tech businesses and guiding their creative projects. Located in the Saint-Roch neighborhood in the heart of Québec City, it gives access to acceleration and incubation programs, as well as improvement and networking activities. LE CAMP is managed and led by Québec International, Québec's metropolitan economic development agency. For more information, please visit lecampquebec.com.

About BioMark Diagnostics Inc.

BioMark is developing proprietary, non-invasive, and accurate cancer diagnostic solutions, which can help detect, monitor and assess treatment for cancer early and cost effectively. The technology can also be used for measuring response to treatment and potentially for serial monitoring for cancer survivors.

Further information about BioMark is available under its profile on the SEDAR website www.sedar.com and on the CSE website https://thecse.com/

For further information on BioMark, please Contact:

Rashid Ahmed M. Bux
President & CEO
BioMark Diagnostics Inc.
Tel. 604-370-0779
Email: info@biomarkdiagnostics.com

Forward-Looking Information:

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of BioMark. Forward-looking information is based on certain key expectations and assumptions made by the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

The CSE has not reviewed, approved, or disapproved the content of this press release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/61607